PPBT

Purple Biotech Ltd. ADR (PPBT) | Rumor.io

Purple Biotech

PPBT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,248

Bullish sentiment (50-day avg)79%

Price to earnings ratio0

Market capitalization2.4M

Earnings per share-47.6

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-26.5M

Social

What share of all stock conversation is about PPBT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% -0.01

Sep 3

$PPBT has experienced a significant increase in trading volume, with over 70 million shares traded yesterday, suggesting a strong short squeeze.
The company's low float has been cited as a reason to remain optimistic about its future prospects, and some users believe that a partnership or buyout news could lead to a significant increase in value.
There is speculation about the potential for a short squeeze, with some users noting that the current setup looks good and that the shorts are wondering why no one is selling.

Generated by AI

Sentiment

Of the messages about PPBT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	71.43% +71.43	78.65% +0.08	65.46% +2.3
Bearish	100% new	28.57% -71.43	21.35% -0.08	34.54% -2.3

Bullish· Sep 3

The company has a low float, making it difficult to predict when the stock will run higher, and increasing the potential for a short squeeze.
The recent volume surge and RSI action indicate a clean breakout, with bullish momentum and a strong potential for future gains.
Management's execution, particularly with the recent $1.4B deal with big pharma, is crucial for the company's future success, and the appointment of Yael, who closed the deal, is a positive development.

Bearish· Sep 2

The company's short interest is significant, and shorts are having a rough time, with a decision needing to be made asap to cover losses.
The company is engaging in dilutive practices, pumping the stock to manipulate its price, and is expected to offer a reverse split to take the stock below $1.
The company's fundamentals are weak, and it will likely dump its price, with some analysts predicting it will break below $2.40, and may even hit $4.

Generated by AI

Topics

Of the messages about PPBT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	62.5%	4.56%
Technical Analysis	—	—	35.16%	47.67%
Analysts	—	—	0.78%	13.21%
Macro	—	—	1.56%	34.53%
Controversies	—	—	0%	0.03%
Earnings	—	—	0%	0%

Announcements· Jun 11

Purple Biotech presented new preclinical data for IM1240 at EACR 2026, showing strong anti-tumor activity in treatment-resistant patient samples and a favorable safety and pharmacokinetic profile.
IM1240 demonstrated an 8x longer half-life, 16x greater exposure, and 300x safer cytokine release compared to the non-capped variant, with potential for wide dosing windows and therapeutic applications.
The primate data for IM1240 confirmed its platform-level validation, with a profile that big pharma pays billions for, and positioned the company for potential M&A opportunities.

Technical Analysis· Dec 2

$PPBT is forming a bull flag, which could indicate further price increases.
Technical analysis suggests $PPBT may be setting up a cup and handle pattern, with potential price targets at $18.
The stock's current price is near the 50MA, which may provide support and lead to a bounce.

Generated by AI

Community

Of the messages about PPBT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	41.67%	49.95%	43.69%
Newcomers	100%	58.33%	50.05%	56.31%

Regulars· Sep 3

The regulars are focused on the possibility of a short squeeze and the potential for a significant price increase, with some speculating about the best time to buy.
The management's execution and the upcoming business development news, particularly a potential partnership or buyout, are being closely watched, with some speculating about the potential for a 100X return.
The regulars are also observing the stock's technical behavior, including a bullish consolidation and the potential for a break above $2.00 resistance, which could lead to a significant price increase.

Newcomers· Sep 3

Newcomers are optimistic about $PPBT, expecting a potential pop around 2.15.
They are focused on the low float of $PPBT, wondering why others are losing hope.
Some newcomers believe $PPBT will continue to hold its area and are expecting a possible continuation of the trend.

Generated by AI

News

Crude Oil Moves Higher; US Factory Orders Rise In July

27d agoBenzinga

Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection

Purple Biotech (NASDAQ:PPBT) has received a U. S.

27d agoYahoo Finance

Why Is Purple Biotech Stock Gaining Wednesday?

27d agoBenzinga

Top Midday Gainers

Purple Biotech (PPBT) said Wednesday that the US Patent and Trademark Office has issued a "Notice of

28d agoYahoo Finance

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3...

1mo agoBarchart.com

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific...

1mo agoBarchart.com

Also Discussed

Investors talking about PPBT also mention

#	Name	Attention
1	Greenwich LifeSciences, Inc.GLSI	0%0
2	Bristol-Myers Squibb CompanyBMY	0.01%0
3	Cambium Networks CorporationCMBM	0%0
4	SGTX - Sigilon Therapeutics, Inc.	——
5	TRML - Tourmaline Bio, Inc.	——
6	WRK - WestRock Company	——
7	Senti Biosciences Holdings, Inc.SNTI	0%new
8	VCNX - Vaccinex, Inc.	——
9	BCEL - Atreca, Inc.	——
10	Hepion Pharmaceuticals, Inc.HEPA	0%0

Purple Biotech Ltd. ADR

Healthcare
Biotechnology

Purple Biotech Ltd. ADR is a clinical-stage biotechnology company focused on developing first-in-class therapies for cancer. Its current pipeline centers on treatments designed to overcome tumor immune evasion and drug resistance, two major barriers that can limit the effectiveness of oncology care. The company’s programs include antibody-based immunotherapies and small-molecule candidates aimed at the tumor microenvironment, with research directed toward solid tumors and treatment-resistant cancers. Purple Biotech works at the intersection of immuno-oncology and precision drug development, seeking to address complex mechanisms that help cancer cells survive and evade treatment. Headquartered in Rehovot, Israel, Purple Biotech Ltd. ADR is positioned as a specialized cancer-focused developer within the broader biotechnology market.

Website

Location

4 Oppenheimer Street

Rehovot, 7670104

Israel

Social

What share of all stock conversation is about PPBT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% -0.01

Sep 3

$PPBT has experienced a significant increase in trading volume, with over 70 million shares traded yesterday, suggesting a strong short squeeze.
The company's low float has been cited as a reason to remain optimistic about its future prospects, and some users believe that a partnership or buyout news could lead to a significant increase in value.
There is speculation about the potential for a short squeeze, with some users noting that the current setup looks good and that the shorts are wondering why no one is selling.

Generated by AI

Sentiment

Of the messages about PPBT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	71.43% +71.43	78.65% +0.08	65.46% +2.3
Bearish	100% new	28.57% -71.43	21.35% -0.08	34.54% -2.3

Bullish· Sep 3

The company has a low float, making it difficult to predict when the stock will run higher, and increasing the potential for a short squeeze.
The recent volume surge and RSI action indicate a clean breakout, with bullish momentum and a strong potential for future gains.
Management's execution, particularly with the recent $1.4B deal with big pharma, is crucial for the company's future success, and the appointment of Yael, who closed the deal, is a positive development.

Bearish· Sep 2

The company's short interest is significant, and shorts are having a rough time, with a decision needing to be made asap to cover losses.
The company is engaging in dilutive practices, pumping the stock to manipulate its price, and is expected to offer a reverse split to take the stock below $1.
The company's fundamentals are weak, and it will likely dump its price, with some analysts predicting it will break below $2.40, and may even hit $4.

Generated by AI

Topics

Of the messages about PPBT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	62.5%	4.56%
Technical Analysis	—	—	35.16%	47.67%
Analysts	—	—	0.78%	13.21%
Macro	—	—	1.56%	34.53%
Controversies	—	—	0%	0.03%
Earnings	—	—	0%	0%

Announcements· Jun 11

Purple Biotech presented new preclinical data for IM1240 at EACR 2026, showing strong anti-tumor activity in treatment-resistant patient samples and a favorable safety and pharmacokinetic profile.
IM1240 demonstrated an 8x longer half-life, 16x greater exposure, and 300x safer cytokine release compared to the non-capped variant, with potential for wide dosing windows and therapeutic applications.
The primate data for IM1240 confirmed its platform-level validation, with a profile that big pharma pays billions for, and positioned the company for potential M&A opportunities.

Technical Analysis· Dec 2

$PPBT is forming a bull flag, which could indicate further price increases.
Technical analysis suggests $PPBT may be setting up a cup and handle pattern, with potential price targets at $18.
The stock's current price is near the 50MA, which may provide support and lead to a bounce.

Generated by AI

Community

Of the messages about PPBT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	41.67%	49.95%	43.69%
Newcomers	100%	58.33%	50.05%	56.31%

Regulars· Sep 3

The regulars are focused on the possibility of a short squeeze and the potential for a significant price increase, with some speculating about the best time to buy.
The management's execution and the upcoming business development news, particularly a potential partnership or buyout, are being closely watched, with some speculating about the potential for a 100X return.
The regulars are also observing the stock's technical behavior, including a bullish consolidation and the potential for a break above $2.00 resistance, which could lead to a significant price increase.

Newcomers· Sep 3

Newcomers are optimistic about $PPBT, expecting a potential pop around 2.15.
They are focused on the low float of $PPBT, wondering why others are losing hope.
Some newcomers believe $PPBT will continue to hold its area and are expecting a possible continuation of the trend.

Generated by AI

Purple Biotech

Social

Sep 3

Bullish· Sep 3

Bearish· Sep 2

Announcements· Jun 11

Technical Analysis· Dec 2

Regulars· Sep 3

Newcomers· Sep 3

Crude Oil Moves Higher; US Factory Orders Rise In July

Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection

Why Is Purple Biotech Stock Gaining Wednesday?

Top Midday Gainers

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Also Discussed

Purple Biotech Ltd. ADR

Company Information

Location

Crude Oil Moves Higher; US Factory Orders Rise In July

Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection

Why Is Purple Biotech Stock Gaining Wednesday?

Top Midday Gainers

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Also Discussed

Social

Sep 3

Bullish· Sep 3

Bearish· Sep 2

Announcements· Jun 11

Technical Analysis· Dec 2

Regulars· Sep 3

Newcomers· Sep 3